Back to Journals » Vascular Health and Risk Management » Volume 9

Lipid management in 13,000 high risk cardiovascular patients treated under daily practice conditions: LIMA Registry

Authors Schaefer J, Gitt A, Sonntag F, Weizel A, Jannowitz C, Karmann B, Pittrow D, Bestehorn K, Patrick Goldstein D

Received 18 August 2012

Accepted for publication 29 September 2012

Published 21 February 2013 Volume 2013:9 Pages 71—80

DOI https://doi.org/10.2147/VHRM.S37143

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4


Juergen R Schaefer,1 Anselm K Gitt,2 Frank Sonntag,3 Achim Weizel,4 Christina Jannowitz,5 Barbara Karmann,5 David Pittrow,6 Kurt Bestehorn6

1UKGM Klinikum Marburg, Philipps-Universität Marburg, Marburg/Lahn, Germany; 2Stiftung Institut für Herzinfarktforschung an der Universität Heidelberg, Ludwigshafen, Germany; 3Private Practice, Henstedt-Ulzburg, Germany; 4Vorsitzender der DGFF (Lipid-Liga) e.V. Planegg, Germany; 5MSD SHARP and DOHME GmbH, Haar, 6Institut für Klinische Pharmakologie, Dresden, Germany

Aims: We aimed to document the drug management of patients at high cardiovascular risk in daily practice, with the special focus on lipid-lowering treatment.
Methods and results: In this prospective noninterventional study in 2387 outpatient centers throughout Germany, a total of 13,942 high-risk patients (mean age 65.7 years, 61.6% males) were treated with simvastatin 40 mg/day at entry as monotherapy. All patients were followed up for 12 months in terms of drug utilization, laboratory values, target attainment, and clinical events (including death, hospitalization, vascular events, and dialysis). Patients had coronary heart disease in 35.0%, diabetes mellitus in 24.4%, and the combination of coronary heart disease plus diabetes mellitus in 25.7%. In 21% of patients, a cholesterol absorption inhibitor was added to statin therapy at the entry visit, and in 23%, this was added at the follow up visit 6 months later. The target values for low-density lipoprotein-cholesterol (<2.6 mmol/L) were reached by 31.8% of patients at entry and by 50.0% at the end of this registry after 12 months. Mean blood pressure decreased (from 135.9/80.5 mmHg at baseline) by 3.1/1.9 mmHg after 12 months. In patients with documented diabetes, the targeted glycated hemoglobin (HbA1c <6.5%) was reached by 33.5% at baseline and by 40.0% after 12 months. Clinical events occurred in 11.7% of patients between baseline and month 6, and in 12.0% between months 6 and 12.
Conclusion: In patients at high risk for cardiovascular events, comprehensive management under daily practice conditions leads to improvement of lipid, glucose, and blood pressure parameters. There is a need to improve secondary prevention among high-risk patients.

Keywords: dyslipidemia, observation, treatment, risk factors, coronary heart disease, cardiovascular disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]